SAGE Therapeutics (SAGE) Misses Q3 EPS by 69c

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($3.37), $0.69 worse than the analyst estimate of ($2.68). Revenue for the quarter came in at $2.72 million versus the consensus estimate of $4.63 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Dell’s earning report was bullish for Intel CPU demand, analyst says
• Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral